{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:36:43Z","timestamp":1791920203833,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,21]]},"DOI":"10.7759\/cureus.17352","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T17:14:39Z","timestamp":1629566079000},"source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Alisha","family":"Sapkota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajra","family":"Khurshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa A","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry R","family":"Went","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Depression Fact Sheet. (2020). Accessed: April 27 2021: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/depression."},{"key":"ref2","unstructured":"National Institute of Mental Health. Statistics. Major Depression. (2019). Accessed: April 27 2021: https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression.shtml."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15092028","article-title":"Suicide risk and mental disorders","volume":"15","author":"Br\u00e5dvik L","year":"2018","unstructured":"Br\u00e5dvik L. Suicide risk and mental disorders. Int J Environ Res Public Health. 2018, 15:2028. 10.3390\/ijerph15092028","journal-title":"Int J Environ Res Public Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush AJ","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, et al.. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006, 163:1905-17. 10.1176\/ajp.2006.163.11.1905","journal-title":"Am J Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.02.010","article-title":"Ketamine and the next generation of antidepressants with a rapid onset of action","volume":"123","author":"Machado-Vieira R","year":"2009","unstructured":"Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009, 123:143-50. 10.1016\/j.pharmthera.2009.02.010","journal-title":"Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2015.17.2\/dionescu","article-title":"Pharmacological approaches to the challenge of treatment-resistant depression","volume":"17","author":"Ionescu DF","year":"2015","unstructured":"Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015, 17:111-26. 10.31887\/DCNS.2015.17.2\/dionescu","journal-title":"Dialogues Clin Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/070674370705200108","article-title":"Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods","volume":"52","author":"Berlim MT","year":"2007","unstructured":"Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007, 52:46-54. 10.1177\/070674370705200108","journal-title":"Can J Psychiatry"},{"key":"ref8","article-title":"Definition of treatment-resistant depression in the Medicare Population","author":"Gaynes BN","year":"2018","unstructured":"Gaynes BN, Asher G, Gartlehner G, et al.. Definition of treatment-resistant depression in the Medicare Population. Agency for Healthcare Research and Quality, Rockville, MD; 2018."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos D","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020, 16:221-34. 10.2147\/NDT.S198774","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S264813","article-title":"Management of treatment-resistant depression in real-world clinical practice settings across Asia","volume":"16","author":"Wang G","year":"2020","unstructured":"Wang G, Han C, Liu CY, et al.. Management of treatment-resistant depression in real-world clinical practice settings across Asia. Neuropsychiatr Dis Treat. 2020, 16:2943-59. 10.2147\/NDT.S264813","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh JB","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly E, et al.. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016, 80:424-31. 10.1016\/j.biopsych.2015.10.018","journal-title":"Biol Psychiatry"},{"key":"ref12","unstructured":"FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic. Case Med Res. (2019). Accessed. April 29 2021: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depre...."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000510703","article-title":"Post-Marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon C","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-Marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom. 2021, 90:41-8. 10.1159\/000510703","journal-title":"Psychother Psychosom"},{"key":"ref14","unstructured":"Ketamine-like drug for depression could get UK licence within the year. (2019). Accessed. April 29 2021: https:\/\/www.theguardian.com\/science\/2019\/jul\/12\/ketamine-like-drug-for-depression-could-get-uk-licence-within-the-year."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001395","article-title":"Esketamine: a drug to treat resistant depression that brings more questions than answers","volume":"41","author":"Mischel NA","year":"2021","unstructured":"Mischel NA, Balon R. Esketamine: a drug to treat resistant depression that brings more questions than answers. J Clin Psychopharmacol. 2021, 41:233-5. 10.1097\/JCP.0000000000001395","journal-title":"J Clin Psychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin M","year":"2019","unstructured":"Fedgchin M, Trivedi M, Daly EJ, et al.. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019, 22:616-30. 10.1093\/ijnp\/pyz039","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly Initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova V","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, et al.. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly Initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019, 176:428-38. 10.1176\/appi.ajp.2019.19020172","journal-title":"Am J Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross R","year":"2020","unstructured":"Ochs-Ross R, Daly EJ, Zhang Y, et al.. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020, 28:121-41. 10.1016\/j.jagp.2019.10.008","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly EJ","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, et al.. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019, 76:893-903. 10.1001\/jamapsychiatry.2019.1189","journal-title":"JAMA Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs E","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R, et al.. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020, 81:19m12891. 10.4088\/JCP.19m12891","journal-title":"J Clin Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.03.106","article-title":"Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"271","author":"Citrome L","year":"2020","unstructured":"Citrome L, DiBernardo A, Singh J. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2020, 271:228-38. 10.1016\/j.jad.2020.03.106","journal-title":"J Affect Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2021.01.123","article-title":"Post hoc analyses of an open-label long-term study of esketamine nasal spray plus an oral antidepressant comparing results in older versus younger adults with treatment-resistant depression","volume":"29","author":"Ochs-Ross R","year":"2021","unstructured":"Ochs-Ross R, Wajs E, Daly EJ, et al.. Post hoc analyses of an open-label long-term study of esketamine nasal spray plus an oral antidepressant comparing results in older versus younger adults with treatment-resistant depression. Am J Geriatr Psychiatry. 2021, 29:S127-8. 10.1016\/j.jagp.2021.01.123","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000751","article-title":"Esketamine for treatment resistant depression: a trick of smoke and mirrors?","volume":"29","author":"Gastaldon C","year":"2019","unstructured":"Gastaldon C, Papola D, Ostuzzi G, Barbui C. Esketamine for treatment resistant depression: a trick of smoke and mirrors?. Epidemiol Psychiatr Sci. 2019, 29:e79. 10.1017\/S2045796019000751","journal-title":"Epidemiol Psychiatr Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2020.89","article-title":"Are we repeating mistakes of the past? A review of the evidence for esketamine","author":"Horowitz MA","year":"2020","unstructured":"Horowitz MA, Moncrieff J. Are we repeating mistakes of the past? A review of the evidence for esketamine. Br J Psychiatry. 2020, 1-4. 10.1192\/bjp.2020.89","journal-title":"Br J Psychiatry"},{"key":"ref26","article-title":"Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant","volume":"44","author":"Bahr R","year":"2019","unstructured":"Bahr R, Lopez A, Rey JA. Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T. 2019, 44:340-75.","journal-title":"P T"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2652","article-title":"A review of the mechanism of antagonism of N-methyl-D-aspartate receptor by ketamine in treatment-resistant depression","volume":"10","author":"Sattar Y","year":"2018","unstructured":"Sattar Y, Wilson J, Khan AM, et al.. A review of the mechanism of antagonism of N-methyl-D-aspartate receptor by ketamine in treatment-resistant depression. Cureus. 2018, 10:e2652. 10.7759\/cureus.2652","journal-title":"Cureus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.261","article-title":"Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?","volume":"40","author":"Sanacora G","year":"2015","unstructured":"Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?. Neuropsychopharmacology. 2015, 40:259-67. 10.1038\/npp.2014.261","journal-title":"Neuropsychopharmacology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.33","article-title":"The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications","volume":"18","author":"Moylan S","year":"2013","unstructured":"Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2013, 18:595-606. 10.1038\/mp.2012.33","journal-title":"Mol Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5455\/bcp.20161027122045","article-title":"Comment on FDA\u2019s breakthrough therapy designation of intranasal esketamine for the treatment of major depressive disorder with imminent risk of suicide","volume":"26","author":"Thomas R","year":"2016","unstructured":"Thomas R, Cetin M, Baker GB, Dursun SM. Comment on FDA\u2019s breakthrough therapy designation of intranasal esketamine for the treatment of major depressive disorder with imminent risk of suicide. Klinik Psikofarmakol Bulteni. 2016, 26:329-31. 10.5455\/bcp.20161027122045","journal-title":"Klinik Psikofarmakol Bulteni"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: a review","volume":"107","author":"Morgan CJ","year":"2012","unstructured":"Morgan CJ, Curran HV, the Independent Scientific Committee on Drugs (ISCD). Ketamine use: a review. Addiction. 2012, 107:27-38. 10.1111\/j.1360-0443.2011.03576.x","journal-title":"Addiction"},{"key":"ref32","article-title":"Evaluation of the cardiovascular stimulation effects after induction of anaesthesia with ketamine","volume":"2","author":"Suleiman Z","year":"2012","unstructured":"Suleiman Z, IK K, BO B. Evaluation of the cardiovascular stimulation effects after induction of anaesthesia with ketamine. J West Afr Coll Surg. 2012, 2:38-52.","journal-title":"J West Afr Coll Surg"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181612cdc","article-title":"Trapped in the \"K-hole\": overview of deaths associated with ketamine misuse in the UK (1993-2006)","volume":"28","author":"Schifano F","year":"2008","unstructured":"Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH. Trapped in the \"K-hole\": overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol. 2008, 28:114-6. 10.1097\/JCP.0b013e3181612cdc","journal-title":"J Clin Psychopharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2004.08.023","article-title":"An epidemiological study on alcohol\/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000","volume":"153","author":"Cheng JY","year":"2005","unstructured":"Cheng JY, Chan DT, Mok VK. An epidemiological study on alcohol\/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000. Forensic Sci Int. 2005, 153:196-201. 10.1016\/j.forsciint.2004.08.023","journal-title":"Forensic Sci Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/65409-efficacy-and-safety-of-intranasal-esketamine-in-treatment-resistant-depression-in-adults-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:35Z","timestamp":1707506975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/65409-efficacy-and-safety-of-intranasal-esketamine-in-treatment-resistant-depression-in-adults-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.17352","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,21]]}}}